| Issue Date | Title | Author(s) | Type | Мp-cat. |
| 2023 | A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care | El-Galaly, Tarec Christoffer; ...; Antić, Darko A.   ; ...; (broj koautora 16) | Article | |
| 2025 | Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA) | Passiglia, Francesco; ...; Secen, Nevena; ...; (broj, koautora 36) | Article | |
| 2021 | EPROPA: The European program for routine testing of patients with advanced lung cancer | Passiglia, F; ...; Secen, Nevena M; ...; (broj, koautora 20) | Conference Paper | |
| 2026 | European S2k guidelines on management of autoimmune blistering diseases in children and adolescents | Nanda, A; ...; Nikolic, M; ...; (broj, koautora 32) | Article | |
| 2024 | POD1UM-304: Phase III study of retifanlimab plus platinum-based chemotherapy (Chemo) as first-line (1L) therapy for nonsquamous or squamous metastatic nonesmall cell lung cancer (mNSCLC) | Lu, S; Vynnychenko, O; Kulyaba, Y; Kuchava, V; Ibrahim, A; Moiseenko, FV; Arslan, C; Nguyen, DT; Zhang, M; Petrovic, MD;
Cicin, I; Bibichadze, K; Cil, T; Cornfeld, M; Tian, C; Munteanu, M; Sette, CVDM; Bondarenko, I;
| Conference Paper | |
| 2025 | Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study | Lu, Shun; ...; Petrovic, Marina ; ...; (broj, koautora 22) | Article | |
| 2025 | World vitiligo day: a model for grassroots medical activism and pharmaceutical innovation | Valle, Y; Soto, CM Arenas; Kassymkhanova, AA; Ocampo, Candiani J; Gondokaryono, SP; Binic, I; Thuong, NV; Cunha, PR; Hercogova, J; Gao, XH;
Parsad, D; Lim, HW; Lotti, T; Sigova, J;
| Article | |